Posted by Joe on his Facebook page... https:/
Post# of 36566
(Total Views: 461)
Posted On: 06/21/2020 10:28:54 AM
Posted by Joe on his Facebook page...
https://video.foxbusiness.com/v/6165875780001/#sp=show-clips
This aired Friday, Saturday, and Sunday on Fox Business Maria Bartiromo’s Wall Street. Nantkwest’s CEO Dr. Patrick Soon-Shiong (also owns LA Times and other big businesses) talks about their “combo” spike and nuclear protein vaccine to activate B and T cells (interestingly their tech is also based on cancer vaccines). He discusses the importance of T cell response (first time I’ve seen this expressed publicly which is the main thrust of Generex Vaccines).
Nantkwest’s vaccine is adeno vector based; same risks as other versions with added risk of including additional nuclear protein. Plus there are better T cell targets than nuclear protein, like our ii-key peptides.
He states they’ve applied to BARDA but haven’t yet received a response. I find this encouraging because Nantkwest checks all the boxes for BARDA support, so we’re both in the same boat, except our vaccine has many scientific and commercial advantages over this and ours is a platform technology, but for sure they do NOT have 10 year data that proves upon a shadow of a doubt that we protect people with our vaccines as evident from our phase 2b just recently peer reviewed and published 10 year significant, positive data in one of the largest adjuvant breast cancer studies ever done, long term memory not just antibodies is the key with COVID 19, all the patients in our control arm (non vaccine) are all diseased, in our vaccine arm after 10 years our patient’s cancer does not come back, triple negative patients approx 90 out of 100 patients get their cancer back within the first 3 to 5 years, we protect them with our vaccine.
https://video.foxbusiness.com/v/6165875780001/#sp=show-clips
This aired Friday, Saturday, and Sunday on Fox Business Maria Bartiromo’s Wall Street. Nantkwest’s CEO Dr. Patrick Soon-Shiong (also owns LA Times and other big businesses) talks about their “combo” spike and nuclear protein vaccine to activate B and T cells (interestingly their tech is also based on cancer vaccines). He discusses the importance of T cell response (first time I’ve seen this expressed publicly which is the main thrust of Generex Vaccines).
Nantkwest’s vaccine is adeno vector based; same risks as other versions with added risk of including additional nuclear protein. Plus there are better T cell targets than nuclear protein, like our ii-key peptides.
He states they’ve applied to BARDA but haven’t yet received a response. I find this encouraging because Nantkwest checks all the boxes for BARDA support, so we’re both in the same boat, except our vaccine has many scientific and commercial advantages over this and ours is a platform technology, but for sure they do NOT have 10 year data that proves upon a shadow of a doubt that we protect people with our vaccines as evident from our phase 2b just recently peer reviewed and published 10 year significant, positive data in one of the largest adjuvant breast cancer studies ever done, long term memory not just antibodies is the key with COVID 19, all the patients in our control arm (non vaccine) are all diseased, in our vaccine arm after 10 years our patient’s cancer does not come back, triple negative patients approx 90 out of 100 patients get their cancer back within the first 3 to 5 years, we protect them with our vaccine.
(3)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.